Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lu, Wei ^a,b   Cao, Yang ^a,c   Zhang, Yijian ^c   Li, Sheng ^d   Gao, Jian ^e   Wang, Xu An ^a   Mu, Jiasheng ^a,c   Hu, Yun Ping ^c   Jiang, Lin ^c   Dong, Ping ^a   Gong, Wei ^a,c   Liu, Yingbin ^a,c  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; MEMBRANE PROTEIN; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ADENOCARCINOMA; ADULT; AGED; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; GALLBLADDER TUMOR; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THYROID HORMONES; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84973594571     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26351     Document Type: Article

References (30)

1. Gourgiotis, S. et al. Gallbladder cancer. Am J Surg 196, 252-264, doi: 10.1016/j.amjsurg.2007.11.011 (2008).
2. Reddy, S. K. & Clary, B. M. Surgical management of gallbladder cancer. Surg Oncol Clin N Am 18, 307-324, ix, doi: 10.1016/j. soc.2008.12.004 (2009).
3. Andren-Sandberg, A. & Deng, Y. Aspects on gallbladder cancer in 2014. Curr Opin Gastroenterol 30, 326-331, doi: 10.1097/MOG.0000000000000068 (2014).
4. Jayaraman, S. & Jarnagin, W. R. Management of gallbladder cancer. Gastroenterol Clin North Am 39, 331-342, x, doi: 10.1016/j. gtc.2010.02.006 (2010).
5. Bizama, C. et al. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev 41, 222-234, doi: 10.1016/j.ctrv.2015.01.003 (2015).
6. Wang, C. et al. Clinicopathological significance of SOX4 expression in primary gallbladder carcinoma. Diagn Pathol 7, 41, doi: 10.1186/1746-1596-7-41 (2012).
7. Tan, Z. et al. NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells. Mol Cell Biochem 369, 27-33, doi: 10.1007/s11010-012-1365-0 (2012).
8. Li, W., Liu, J. & Zhao, Y. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells. Mol Carcinog 53, 403-412, doi: 10.1002/mc.21988 (2014).
9. Kwon, O. H. et al. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys Res Commun 423, 38-44, doi: 10.1016/j.bbrc.2012.05.063 (2012).
10. Wong, T. S. et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int J Cancer 123, 251-257, doi: 10.1002/ijc.23583 (2008).
11. Li, W., Xu, Z., Hong, J. & Xu, Y. Expression patterns of three regulation enzymes in glycolysis in esophageal squamous cell carcinoma: association with survival. Med Oncol 31, 118, doi: 10.1007/s12032-014-0118-1 (2014).
12. Nemazanyy, I., Espeillac, C., Pende, M. & Panasyuk, G. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans 41, 917-922, doi: 10.1042/BST20130034 (2013).
13. Wang, H. J. et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc Natl Acad Sci USA 111, 279-284, doi: 10.1073/pnas.1311249111 (2014).
14. Wong, N., De Melo, J. & Tang, D. PKM2, a Central Point of Regulation in Cancer Metabolism. Int J Cell Biol 2013, 242513, doi: 10.1155/2013/242513 (2013).
15. Yang, W. & Lu, Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12, 3154-3158, doi: 10.4161/cc.26182 (2013).
16. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17, 1471-1474, doi: 10.1245/s10434-010-0985-4 (2010).
17. Lee, H. S., Lee, H. K., Kim, H. S., Yang, H. K. & Kim, W. H. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 200, 39-46, doi: 10.1002/path.1288 (2003).
18. Drachenberg, C. B., Papadimitriou, J. C., Balaton, A. J. & Vaury, P. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 125, 471, doi: 10.1043/1543-2165(2001)125<471b:IR> 2.0.CO;2 (2001).
19. Taylor, C. R. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 124, 945-951, doi: 10.1043/0003-9985(2000)124<0945:TTTATS>2.0.CO;2 (2000).
20. O'Leary, T. J. Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol 9, 3-8 (2001).
21. Li, M. et al. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol 34, 3995-4000, doi: 10.1007/s13277-013-0988-4 (2013).
22. Dang, C. V. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. Sci Signal 2, pe75, doi: 10.1126/scisignal.297pe75 (2009).
23. Hitosugi, T. et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2, ra73, doi: 10.1126/scisignal.2000431 (2009).
24. Li, J. et al. PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol 16, 200-207, doi: 10.1007/s12094-013-1063-8 (2014).
25. David, C. J., Chen, M., Assanah, M., Canoll, P. & Manley, J. L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364-368, doi: 10.1038/nature08697 (2010).
26. Desai, S. et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget 5, 8202-8210, doi: 10.18632/oncotarget.1159 (2014).
27. Warner, S. L., Carpenter, K. J. & Bearss, D. J. Activators of PKM2 in cancer metabolism. Future Med Chem 6, 1167-1178, doi: 10.4155/fmc.14.70 (2014).
28. Li, L., Zhang, Y., Qiao, J., Yang, J. J. & Liu, Z. R. Pyruvate kinase M2 in blood circulation facilitates tumor growth by promoting angiogenesis. J Biol Chem 289, 25812-25821, doi: 10.1074/jbc.M114.576934 (2014).
29. Goldberg, M. S. & Sharp, P. A. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 209, 217-224, doi: 10.1084/jem.20111487 (2012).
30. Li, Z., Yang, P. & Li, Z. The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta 1846, 285-296, doi: 10.1016/j.bbcan.2014.07.008 (2014).